Anti-Cathepsin-A Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the amino-terminal region of human Cathepsin-A (CTSA), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog
UniProt
P10619
Size
100ug
Cat. #
RP1CathepsinA

In stock

SKU
RP-CathepsinA

Options

As low as: $130.00

Target Overview

Cathepsin-A (CTSA, UniProt P10619), also known as lysosomal protective protein (PPCA) or carboxypeptidase C (EC 3.4.16.5), is a 480-amino acid serine carboxypeptidase localized to lysosomes. The protein serves dual roles: it functions as a protective chaperone essential for the stability and enzymatic activity of beta-galactosidase and neuraminidase-1 (NEU1), and it also exhibits intrinsic carboxypeptidase activity capable of deamidating tachykinins and processing bioactive peptides. CTSA forms a high-molecular-weight lysosomal multienzyme complex with beta-galactosidase and NEU1, preventing their premature degradation and ensuring proper trafficking. Deficiency in CTSA results in galactosialidosis, a rare autosomal recessive lysosomal storage disorder characterized by combined deficiency of beta-galactosidase and neuraminidase-1. Researchers study CTSA in the context of lysosomal enzyme trafficking, protein quality control mechanisms, and lysosomal storage diseases. The protein is also implicated in cardiovascular pathology and metabolic regulation, as recent work has identified defects in lysosomal enzyme sorting associated with pulmonary arterial hypertension and metabolic disease phenotypes.

Background

Cathepsin-A is a multifunctional lysosomal protein that operates both as a protective chaperone and as a serine carboxypeptidase. Its protective function is essential for the formation and stability of the lysosomal multienzyme complex containing beta-galactosidase and NEU1. In the absence of functional CTSA, both beta-galactosidase and NEU1 are rapidly degraded, leading to secondary enzyme deficiencies. The carboxypeptidase activity of CTSA processes substrates including endothelin-1, substance P, oxytocin, and bradykinin, implicating the enzyme in the regulation of neuropeptide signaling and blood pressure homeostasis. CTSA is synthesized as a 54 kDa precursor that undergoes proteolytic maturation in lysosomes to generate a two-chain active form. Recent investigations have expanded understanding of CTSA beyond classical lysosomal storage disease. Lin et al. (2026) utilized patient-specific midbrain organoids to model neuronopathic Gaucher disease, demonstrating the interconnected pathology of lysosomal enzyme deficiencies including CTSA-related defects. Xiao et al. (2026) identified defects in lysosomal enzyme trafficking and sorting, including altered CTSA localization, as a feature of irreversible pulmonary arterial hypertension, suggesting broader cardiovascular roles. Gadara et al. (2026) characterized age-dependent variability in lysosomal hydrolase expression, including CTSA, with implications for pharmacokinetics of small molecule and biologic drugs that undergo lysosomal degradation. TPB offers two rabbit polyclonal antibodies raised against the amino-terminal region of human Cathepsin-A, validated for Western blot applications. Both reagents recognize human CTSA with validated reactivity and show predicted cross-reactivity with mouse, rat, primate, and canine orthologs based on sequence conservation.

References

  1. Lin Y et al (2026) Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. Elife. PubMed · 10.7554/eLife.109518
  2. Xiao G et al (2026) Defect in lysosomal enzyme trafficking and sorting is associated with irreversibility of pulmonary arterial hypertension. Front Cardiovasc Med. PubMed · 10.3389/fcvm.2026.1763556
  3. Gadara D et al (2026) Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs. Clin Pharmacol Ther. PubMed · 10.1002/cpt.70341

Additional Specifications

Gene Symbol CTSA
UniProt ID P10619
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog
Pack Size 100ug
Immunogen (Amino end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 29-79.
Immunogen (light chain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 327-480.
Alternate Names CTSA, Lysosomal protective protein, Protective protein cathepsin A, PPCA, Carboxypeptidase C, Carboxypeptidase L, Protective protein for beta-galactosidase, EC 3.4.16.5

Frequently Asked Questions

What molecular weight band should I expect for Cathepsin-A on Western blot?

Full-length Cathepsin-A migrates at approximately 54 kDa corresponding to the precursor form. In lysosomes, the mature protein is proteolytically processed into a two-chain form consisting of a 32 kDa heavy chain and a 20 kDa light chain that remain associated. Depending on cell type and lysis conditions, you may observe the 54 kDa precursor, the processed chains, or both. Lysosome-enriched fractions typically show more abundant processed forms. The antibody is raised against residues spanning both chains, so it should detect precursor and mature forms, though band intensity may vary.

Does this antibody work for immunofluorescence detection of lysosomal Cathepsin-A?

Triple Point Biologics antibodies are validated for Western blot and immunohistochemistry; immunofluorescence performance has not been systematically validated for this clone. However, many researchers successfully adapt our antibodies to IF applications. For lysosomal Cathepsin-A, try starting dilutions between 1:100 and 1:500 with standard paraformaldehyde fixation and permeabilization. Include a co-stain with LAMP1 or LAMP2 to confirm lysosomal localization. Test on a known CTSA-positive cell line such as HeLa or fibroblasts before moving to experimental samples.

What is the recommended starting dilution for Western blot with this Cathepsin-A antibody?

The validated dilution is 1:1000 for Western blot. This has been tested against human lysates. Optimal dilution depends on expression level, which varies by tissue and cell type. Cathepsin-A is broadly expressed but most abundant in kidney, liver, and placenta. For initial experiments with cultured cells, start at 1:1000 in 5% non-fat milk or BSA in TBST with overnight incubation at 4°C. If signal is weak in low-expression samples, titre up to 1:500. If background is high, increase blocking time or dilute to 1:2000.

Will this antibody cross-react with mouse or rat Cathepsin-A?

The antibody is validated against human Cathepsin-A. Mouse and rat are listed as potential cross-reactive species based on sequence homology. Human CTSA shares approximately 85% identity with mouse and rat orthologs across the immunogen region. Cross-reactivity has not been experimentally confirmed in-house. If working with rodent samples, include a positive control lysate from mouse or rat tissue known to express Cathepsin-A at detectable levels, such as kidney or liver. Expect similar band patterns to human, but confirm specificity with a CTSA-deficient or knockdown control if available.

What cell lysate should I use as a positive control for Cathepsin-A expression?

HeLa, HEK293, or primary human fibroblasts provide reliable positive controls, as Cathepsin-A is constitutively expressed in lysosomes of most cell types. For tissue lysates, human placenta, kidney cortex, or liver show high endogenous expression. Load 20-30 µg total protein per lane. Lysosome-enriched fractions will yield stronger signal than whole-cell lysates. A good negative control strategy is siRNA knockdown of CTSA in your test cell line, or comparison to fibroblasts from a galactosialidosis patient if available through a repository, since these lack functional Cathepsin-A protein.

How should I store this antibody and what is the expected shelf life?

Store the antibody at -20°C in the original formulation. Avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. For routine use, aliquot into single-use volumes immediately upon receipt. Working aliquots may be kept at 4°C for up to one month if sodium azide preservative is present; check the product datasheet. Do not store diluted antibody in working buffer for more than one week. Under proper storage at -20°C without freeze-thaw, polyclonal antibodies from this production lot typically remain stable for at least two years from the manufacturing date.

Does Cathepsin-A run as a single band or are there multiple isoforms to consider?

Cathepsin-A does not have alternatively spliced isoforms, but the single gene product undergoes post-translational processing. You will typically see the 54 kDa precursor and, depending on sample type, the mature processed form as separate 32 kDa and 20 kDa chains. These chains remain non-covalently associated in the native complex but may separate under reducing SDS-PAGE. If you see additional higher molecular weight bands above 54 kDa, these likely represent the multienzyme complex with beta-galactosidase and NEU1, which can survive mild lysis conditions. These complexes dissociate in standard Laemmli buffer with boiling.

Can this antibody detect the Cathepsin-A complex with beta-galactosidase and neuraminidase-1?

This antibody recognizes denatured Cathepsin-A and is validated for Western blot under reducing conditions, where the high-molecular-weight lysosomal complex dissociates. For detecting the intact approximately 1.3 MDa multienzyme complex, you would need non-denaturing methods such as Blue Native PAGE or co-immunoprecipitation followed by Western blot for individual components. If your goal is to confirm complex formation, immunoprecipitate with anti-Cathepsin-A under native conditions, then blot the precipitate for beta-galactosidase or NEU1. Standard denaturing Western blot will show only monomeric CTSA species.

Western blot validation for RP-CathepsinA — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Cathepsin-A: Amino end — WB validation
WB · Panel 1 Cathepsin-A: Amino end
Cathepsin-A: light chain — WB validation
WB · Panel 2 Cathepsin-A: light chain

Custom validation studies available on request — contact us.

Also known as:

  • CTSA
  • Lysosomal protective protein
  • Protective protein cathepsin A
  • PPCA
  • Carboxypeptidase C
  • Carboxypeptidase L
  • Protective protein for beta-galactosidase
  • EC 3.4.16.5
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →